NASDAQ · COOHealthcareOphthalmic Goods

The Cooper Companies financials

$56.63+0.11%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Oct 31
FY24
Oct 31
FY24
Feb 3
FY23
Oct 31
FY23
Jan 28
FY22
Oct 31
FY22
Jan 29
FY21
Oct 31
FY21
Jan 30
FY20
Oct 31
Revenue$4.09B$3.90B$3.07B$3.59B$3.32B$3.31B$3.20B$2.92B$2.23B$2.43B
Gross profit$2.68B$2.60B$1.32B$2.36B$1.45B$2.14B$1.07B$1.96B$311.2M$1.53B
Gross margin65.5%66.6%43.1%65.6%43.9%64.7%33.4%66.9%13.9%63.1%
Operating income$682.9M$705.7M$67.8M$533.1M$182.8M$507.6M$196.2M$505.8M-$595.6M$311.8M
Net income$374.9M$392.3M$29.1M$294.2M$162.7M$385.8M$154.5M$2.94B-$488.7M$238.4M
Net margin9.2%10.1%0.9%8.2%4.9%11.7%4.8%100.8%−21.9%9.8%
Diluted EPS$1.87$1.96$0.46$1.48$2.26$1.94$2.00$59.16$-6.77$4.81
EBITDA$1.06B$1.08B$134.0M$900.8M$264.2M$853.7M$275.9M$846.9M-$354.0M$598.9M
Operating cash flow$796.1M$709.3M$162.4M$607.5M$201.4M$692.4M$171.4M$738.6M-$153.8M$486.6M
Free cash flow$433.7M$288.1M$107.4M$215.0M$146.5M$450.4M$138.4M$524.2M-$184.9M$176.2M
Diluted shares200.0M200.4M63.4M199.3M72.1M198.8M77.3M49.8M72.2M49.6M

Balance sheet

Period endOct 31Oct 31Feb 3Oct 31Jan 28Oct 31
Cash & equivalents$110.6M$107.6M$49.2M$120.8M$58.8M$138.2M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$2.51B$2.58B$427.1M$2.57B$281.0M$2.76B
Total assets$12.39B$12.32B$2.08B$11.66B$2.01B$11.49B
Total liabilities$4.16B$4.23B$1.71B$4.11B$1.57B$4.32B
Shareholders' equity$8.24B$8.08B$359.2M$7.55B$432.9M$7.17B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology